Celcuity Inc. 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: Celcuity Inc. (CELC)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Celcuity is a clinical-stage biotechnology company developing targeted therapies for solid tumors. Its lead candidate, gedatolisib, is a pan-class I PI3K/mTOR inhibitor. The company has no commercial revenue to date and relies on financing to fund operations.
Key Milestone: In January 2026, the FDA accepted Celcuity's New Drug Application (NDA) for gedatolisib in HR+/HER2-, PIK3CA wild-type advanced breast cancer, granting Priority Review with a PDUFA target date of July 17, 2026.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(177.0) million | $(111.8) million |
| Operating Expenses | $172.2 million | $113.3 million |
| Research & Development | $145.0 million | $104.2 million |
| General & Administrative | $27.2 million | $9.1 million |
| Cash & Short-Term Investments | $441.5 million | $235.1 million |
| Total Debt (Principal) | $338.8 million | $130.0 million |
| Accumulated Deficit | $(448.9) million | $(271.9) million |
Note: Debt includes $201.3 million in 2.750% Senior Notes due 2031 and $130.0 million in secured Term Loans.
Material Changes vs. Prior Period
- Increased Burn Rate: Net loss increased 58% to $177.0 million, driven by a 39% rise in R&D expenses (due to clinical trial costs and a $5.0 million Pfizer milestone payment) and a 200% rise in G&A expenses (primarily due to stock-based compensation and commercial launch preparations).
- Capital Raising: The company significantly expanded its balance sheet through financing activities, raising approximately $360.6 million in net cash from financing in 2025. This included a $194.9 million convertible note offering and a $91.6 million equity offering.
- Debt Structure: Total indebtedness grew from $130.0 million to $338.8 million following the issuance of Senior Notes and the drawdown of a $30.0 million Term D Loan upon achieving a clinical milestone.
Guidance, Outlook, and Risks
Outlook: Management believes current cash, cash equivalents, and short-term investments ($441.5 million), combined with available borrowings, are sufficient to fund operations through 2027. The company anticipates generating revenue in the second half of 2026 if FDA approval is granted.
Clinical Pipeline Status:
- VIKTORIA-1 (Breast Cancer): Phase 3 results for the PIK3CA wild-type cohort showed statistically significant improvements in Progression-Free Survival (PFS) compared to fulvestrant. The PIK3CA mutant cohort data is expected in Q2 2026.
- VIKTORIA-2 (Breast Cancer): Phase 3 first-line trial is ongoing; safety run-in completed in Q1 2026.
- CELC-G-201 (Prostate Cancer): Phase 1b/2 trial is ongoing with promising preliminary data.
Key Risks:
- Regulatory Approval: Failure to obtain FDA approval for gedatolisib would materially impact the business.
- Liquidity: Continued operating losses require additional capital; future financing may be dilutive or restrictive.
- Intellectual Property: Dependence on a license agreement with Pfizer; termination could halt commercialization.
- Debt Obligations: Significant indebtedness limits cash flow flexibility and exposes the company to interest rate and covenant risks.
Investor Verification Checklist
- FDA Decision Timeline: Verify the PDUFA target date of July 17, 2026, and monitor for any advisory committee meetings or Complete Response Letters.
- Cash Runway: Confirm the sufficiency of the $441.5 million cash balance against projected commercialization costs and debt service obligations.
- Debt Covenants: Review the terms of the Senior Notes and A&R Loan Agreement for liquidity covenants and potential dilution upon conversion.
- Commercial Readiness: Assess the company's progress in hiring a sales force and establishing manufacturing/distribution partnerships for a potential 2026 launch.
- Pfizer Milestones: Track future milestone payments due to Pfizer upon commercialization and revenue thresholds.